Biolargo, Inc. financial data

Symbol
BLGO on OTC
Industry
Chemicals & Allied Products
Location
14921 Chestnut St., Westminster, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
NUWAY MEDICAL INC (to 4/3/2007), NUWAY ENERGY INC (to 2/5/2003), LATIN AMERICAN CASINOS INC (to 2/15/2001)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 228 % -17%
Quick Ratio 6.64 % -15.6%
Debt-to-equity 58.1 % +33%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 301M shares +4.03%
Common Stock, Shares, Outstanding 293M shares +5.2%
Entity Public Float 40.9M USD +0.38%
Common Stock, Value, Issued 202K USD +4.66%
Weighted Average Number of Shares Outstanding, Basic 300M shares +4.36%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.53M USD +18%
Operating Income (Loss) -3.72M USD +25.4%
Earnings Per Share, Basic -0.01 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.88M USD +27.6%
Accounts Receivable, after Allowance for Credit Loss, Current 3.21M USD +121%
Inventory, Net 238K USD +95.1%
Assets, Current 7.39M USD +57.6%
Property, Plant and Equipment, Net 1.81M USD +202%
Operating Lease, Right-of-Use Asset 1.02M USD +31.1%
Other Assets, Noncurrent 70K USD +1.45%
Assets 10.3M USD +57.4%
Accounts Payable, Current 1.56M USD +133%
Employee-related Liabilities, Current 43K USD -77.8%
Contract with Customer, Liability, Current 19K USD +850%
Liabilities, Current 3.2M USD +83.9%
Operating Lease, Liability, Noncurrent 944K USD +35.8%
Liabilities 4.32M USD +58.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -230K USD -42.9%
Retained Earnings (Accumulated Deficit) -148M USD -1.45%
Stockholders' Equity Attributable to Parent 8.58M USD +21.3%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 5.98M USD +56.7%
Liabilities and Equity 10.3M USD +57.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 481K USD
Net Cash Provided by (Used in) Financing Activities 1.08M USD -28.3%
Net Cash Provided by (Used in) Investing Activities -863K USD -1698%
Common Stock, Shares Authorized 550M shares 0%
Common Stock, Shares, Issued 301M shares +4.34%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 797K USD -43.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 12K USD -20%
Deferred Tax Assets, Valuation Allowance 22.3M USD +4.42%
Operating Lease, Liability 1.05M USD +32.4%
Depreciation 122K USD -15.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -2.19M USD +43.1%
Lessee, Operating Lease, Liability, to be Paid 1.84M USD
Operating Lease, Liability, Current 105K USD +8.25%
Lessee, Operating Lease, Liability, to be Paid, Year Two 289K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 282K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.18 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 787K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 296K USD
Deferred Tax Assets, Operating Loss Carryforwards 22.3M USD +4.42%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 245K USD
Additional Paid in Capital 157M USD +2.4%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 338K USD -21.4%
Interest Expense 45K USD -47.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%